588 related articles for article (PubMed ID: 32645228)
1. Angiotensin II receptors: Impact for COVID-19 severity.
Aksoy H; Karadag AS; Wollina U
Dermatol Ther; 2020 Nov; 33(6):e13989. PubMed ID: 32645228
[TBL] [Abstract][Full Text] [Related]
2. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
[TBL] [Abstract][Full Text] [Related]
3. Two hits to the renin-angiotensin system may play a key role in severe COVID-19.
Tseng YH; Yang RC; Lu TS
Kaohsiung J Med Sci; 2020 Jun; 36(6):389-392. PubMed ID: 32492292
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases.
El-Arif G; Khazaal S; Farhat A; Harb J; Annweiler C; Wu Y; Cao Z; Kovacic H; Abi Khattar Z; Fajloun Z; Sabatier JM
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408447
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
6. ACE2 and COVID-19 and the resulting ARDS.
Zhang X; Li S; Niu S
Postgrad Med J; 2020 Jul; 96(1137):403-407. PubMed ID: 32522846
[TBL] [Abstract][Full Text] [Related]
7. Renin-angiotensin system at the interface of COVID-19 infection.
Gul R; Kim UH; Alfadda AA
Eur J Pharmacol; 2021 Jan; 890():173656. PubMed ID: 33086029
[TBL] [Abstract][Full Text] [Related]
8. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
9. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.
Albini A; Di Guardo G; Noonan DM; Lombardo M
Intern Emerg Med; 2020 Aug; 15(5):759-766. PubMed ID: 32430651
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
[TBL] [Abstract][Full Text] [Related]
11. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
South AM; Brady TM; Flynn JT
Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
[TBL] [Abstract][Full Text] [Related]
12. Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists.
Steckelings UM; Sumners C
Clin Sci (Lond); 2020 Nov; 134(22):2987-3006. PubMed ID: 33210709
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells.
Caputo I; Caroccia B; Frasson I; Poggio E; Zamberlan S; Morpurgo M; Seccia TM; Calì T; Brini M; Richter SN; Rossi GP
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563515
[TBL] [Abstract][Full Text] [Related]
14. Therapy with RAS inhibitors during the COVID-19 pandemic.
Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Sun ML; Yang JM; Sun YP; Su GH
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):219-222. PubMed ID: 32164092
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme 2 and kidney diseases in the era of coronavirus disease 2019.
Suh SH; Ma SK; Kim SW; Bae EH
Korean J Intern Med; 2021 Mar; 36(2):247-262. PubMed ID: 33617712
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19.
Sackin H
Med Hypotheses; 2021 Jul; 152():110609. PubMed ID: 34048987
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
Hooper NM; Lambert DW; Turner AJ
Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
[TBL] [Abstract][Full Text] [Related]
19. The ACE-2 in COVID-19: Foe or Friend?
Dalan R; Bornstein SR; El-Armouche A; Rodionov RN; Markov A; Wielockx B; Beuschlein F; Boehm BO
Horm Metab Res; 2020 May; 52(5):257-263. PubMed ID: 32340044
[TBL] [Abstract][Full Text] [Related]
20. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]